Abbott Laboratories (NYSE:ABT) Announces Quarterly Earnings Results, Hits Expectations

Abbott Laboratories (NYSE:ABT) posted its earnings results on Wednesday. The healthcare product maker reported $1.42 EPS for the quarter, hitting the consensus estimate of $1.42, FiscalAI reports. The firm had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.

Abbott Laboratories Stock Performance

NYSE ABT opened at $102.68 on Wednesday. The stock has a market capitalization of $177.67 billion, a price-to-earnings ratio of 33.23, a PEG ratio of 1.93 and a beta of 0.59. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $132.02. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a 50-day moving average of $105.68 and a 200 day moving average of $98.30.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Wall Street Analyst Weigh In

Several research firms have commented on ABT. Citigroup upped their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. raised their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Weiss Ratings raised shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Robert W. Baird started coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $118.88.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Strong third-quarter performance: Abbott reported 14.5% year-over-year sales growth, or 7.0% on a comparable basis. Adjusted diluted EPS was $1.42, and management reaffirmed its full-year EPS guidance, signaling that operating trends remain on track. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Nutrition separation could unlock value: Abbott plans to distribute its approximately $8.5 billion Nutrition business to shareholders as an independent, publicly traded company by the end of 2027. Management expects the separation to give Abbott faster sales growth and a broader margin profile, while allowing both businesses to pursue more focused strategies. Abbott Announces Nutrition Business Separation
• Positive Sentiment: Diagnostics expansion: Abbott received European CE Mark authorization for its Cologuard Plus colorectal cancer screening test, expanding the potential market for its diagnostics portfolio in Europe. Abbott Secures Europe CE Mark for Colorectal Cancer Test
• Neutral Sentiment: Execution risk remains: The Nutrition transaction is not expected to be completed until 2027, leaving investors to evaluate separation costs, tax-free distribution requirements and the eventual growth and margin profiles of both companies.
• Negative Sentiment: Libre faces a more competitive market: Abbott’s FreeStyle Libre continuous glucose monitoring business continues to grow, but rising competition, product improvements from rivals and insurer pressures could limit future pricing and profitability. Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive?

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.